O-188 Phase II study of the EGFR tyrosine kinase inhibitor...

Lung Cancer 2005 / 7 Vol. 49

O-188 Phase II study of the EGFR tyrosine kinase inhibitor erlotinib (Tarceva) in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma

Jackman, D., Lucca, J., Fidias, P., Rabin, M., Lynch, T., Ostler, P., Skarin, A., Temel, J., Johnson, B., Janne, P.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
49
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/s0169-5002(05)80322-8
Date:
July, 2005
File:
PDF, 325 KB
english, 2005
Conversion to is in progress
Conversion to is failed